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Periodontal disease and metabolic illnesses negatively impact the quality of life and, 
eventually, mental health. This study aimed to investigate the effect of Porphyromonas 
gingivalis (W83) oral infection on the development of Alzheimer's disease (AD) 
pathophysiology in a wild-type obese, diabetic (db/db) mouse model. The db/db mice were 
either orally infected with P. gingivalis and  Fusobacterium nucleatum or sham infected for 
16 weeks. The presence of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs) were 
assessed using a silver impregnation technique and subsequently by immunohistochemistry 
for tau and neuroinflammation. The mRNA abundance of a panel of 184 genes was 
performed using quantitative real-time PCR, and the differentially expressed genes were 
analyzed by Ingenuity Pathway Analysis. While no Aβ plaques and NFTs were evident by 
silver impregnation, immunohistochemistry (glial cell markers) of the P. gingivalis-infected 
mice tissue sections exhibited neuroinflammation in the form of reactive microglia and 
astrocytes. Anti-tau immunopositivity, in addition to cells, was prominent in  thickened axons 
of hippocampal CA neurons. The mRNA abundance of crucial genes in the insulin signaling 
pathway (INSR, IGF1, IRS, IDE, PIK3R, SGK1, GYS, GSK3B, AKT1) were upregulated, 
potentially exacerbating insulin resistance in the brain by P. gingivalis oral infection. 
Increased mRNA abundance of several kinases, membrane receptors, transcription factors, 
and pro-inflammatory mediators indicated hyperactivation of intracellular cascades with 
potential for tau phosphorylation and Aβ release in the same infection group. In conclusion, 
P. gingivalis W83 infection of db/db mice provides a disease co-morbidity model with the 
potential to reproduce AD pathophysiology with induced periodontal disease. 
 
 













Chronic periodontal disease is one of the most prevalent human chronic diseases that affect 
the host’s immune response and the periodontal tissues, which if left untreated, leads to 
eventual tooth loss [1]. Porphyromonas gingivalis is considered a keystone pathogen of the 
disease, and is observed in gingival plaque samples of chronic periodontitis patients [2]. The 
encapsulated serotypes of P. gingivalis such as W83 (K1 serotype) are highly effective at 
causing severe disease because of their ability to stimulate the immune system by inducing 
several pro-inflammatory cytokines including (IL)-1β, IL-6, IL-17, interferon (IFN)-γ, and 
tumor necrosis factor (TNF)-α in macrophages and dendritic cells [3]. The pathogenic strains 
can also directly enter the systemic circulation following toothbrushing of inflamed gingivae 
[4], as revealed through microbial analysis of the blood samples from the infected host [5]. 
Lipopolysaccharide (LPS) is also reported to be present in the blood samples of patients with 
periodontal disease [6]. Growing evidence suggests that periodontopathogens play a role in 
the modulation of systemic and non-systemic pathological manifestations, especially 
metabolic syndrome (MetS), which is characterised by the presence of insulin resistance [7] 
and Alzheimer’s disease (AD) [8,9]. 
AD is a neurodegenerative disease characterised by two microscopical lesions, 
namely amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) bound to 
hyperphosphorylated tau protein in the fronto-temporal cerebral cortices [10]. The insoluble 
Aβ deposition and the development of NFT tau protein have a direct connection with the 
intracerebral innate immune response and complement activation [11]. Progression and 
development of Aβ links with microbial infections [12,13], and the inflammatory mediator 
(cytokines) release that always follows the microbial entry into the host [3,14]. While the role 
of P. gingivalis infection in the development of Aβ deposits is unfolding, it is unclear how 
the amyloid precursor protein (APP) processing could lead to Aβ deposition. 
Numerous studies implicate the association of obesity/type-2 diabetes (T2D) with 
periodontal disease [15]. Active periodontal disease can potentially affect glycemic control 
leading to T2D (an example of MetS). T2D patients with periodontitis tend to have fewer 
teeth, and deeper periodontal pockets containing P. gingivalis [16]. The ability of P. 
gingivalis to cause periodontal tissue damage and initiate periodontal pockets is due 
predominantly to its two main virulence factors, which are gingipains and LPS [17]. LPS 
mediates the secretion of pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) contributing to 
hyperglycemia and insulin resistance [18]. Elevated levels of lipid A within the LPS 




apoptotic cells thereby providing a safe santuary for P. gingivalis survival within infected 
neutrophils [19]. P. gingivalis LPS can potentially contribute to the high circulatory level of 
LPS and is commonly found in individuals suffering from obesity and T2D [7]. Although 
LPS in blood plasma in MetS is predominantly of gastrointestinal origin [7], the contribution 
of LPS from P. gingivalis in the circulating blood in MetS is likely, but its overall impact 
remains unclear.  
Growing evidence suggests that periodontitis and MetS together exacerbate the onset 
of AD [20,21]. Currently, longitudinal studies on the intricate association between 
periodontal disease, MetS and AD are scarce. The obesity/type-2 diabetes (db/db) mouse is a 
relevant laboratory model for MetS as they develop identifiable obesity around 3-4 weeks of 
age with an elevated plasma insulin beginning at 10-14 days. Thus, db/db mice provide a 
valuable co-morbidity model that shows clinical signs of periodontitis and MetS for 
investigating AD. We initiated the study to test our hypothesis that chronic induction of P. 
gingivalis via the oral route in db/db mice would stimulate the formation of the pathological 
lesions in the presence of simulated predisposing conditions that co-exitst during AD onset 
and progression [22-25]. Our main objective in this study was to assess the effect of P. 
gingivalis W83 mediated oral infection on Aβ plaque deposition and NFT formation and to 
identify the specific molecular pathways that serve as common molecular drivers during 
inflammation and insulin resistance in vivo  in db/db mice. 
 
Materials and methods 
 
Mice and infection regime 
Obese and type-2 diabetic mice (db/db mice) aged five weeks were purchased from Jackson 
Laboratories, Bar Harbor, MA, USA. Mice at six weeks were randomly assigned to any of 
the three groups, and periodontal disease was induced by orally infecting with 109 colony-
forming unit (CFU/ml) P. gingivalis W83 (n=9), and Fusobacterium nucleatum (ATCC 
49256 ) (n =3) and uninfected (sham mice n=6 as carrier control). The sham mice (sham-
infection and /or control group) received the carboxymethyl cellulose (vehicle control) only 
and the F. nucleatum bacterial infection group (an irrelevant bacteria for AD infection was 
another control group) for the same experimental duration. Mice were orally infected with the 
capsulated P. gingivalis strain W83 (K1 serotype) and F. nucleatum and sham, every other 




euthanized, and tissues (whole brain, for this study) collected for further analysis. One 
cerebral hemisphere was fixed in 10% neutral buffered formalin for microscopy and 
immunohistochemistry and the other cerebral hemisphere was placed into RNA-later and 
stored at -80ºC for gene expression analysis. Brain samples from AD transgenic Tg2576 mice 
with the Swedish mutation (n=3) were obtained from Prof. Roxane O. Carare, Faculty of 
Medicine, University of Southampton, UK, as secondary users of tissue, to act as positive 
controls for Aβ insoluble plaues and for immunohistochemistry for resident central nervous 
system inflammatory cell responses.  
All experimental procedures were performed in accordance with the guidelines of the 
University of Florida Institutional Animal Care and Use Committee (IACUC, protocol 
#201710038) and the University of Central Lancashire, UK (AWERB #RE1718 and RE19/02 
(db/bd mice) and RE/17/06 for  Tg2576 mice brains). 
 
Light Microscopy  
 
The formalin-fixed brain specimens were processed in an automated tissue processor 
(Shandon Citadel 2000, Thermo Scientific) and embedded in paraffin wax as per routine 
methods. The tissue blocks with temporal lobe inclusive of the hippocampus were sectioned 
(5 mm in thickness) using the Leica RM2235 microtome and collected on Superfrost+® glass 
microscope slides (Leica UK). Rehydrated paraffin wax sections from the hippocampus of 
the AD transgenic Tg2576 mice (positive controls) and db/db mice (test specimens) were 
screened for argyrophilic Aβ1-40/42 insoluble plaques using the modified Methenamine 
silver stain described previously [26].  
 
Immunohistochemistry 
Following dewaxing and acohol dehydration steps, the brain tissue sections from the Tg2576 
and the db/db mice were treated with 0.003% H2O2 in  methanol for 20 min at room 
temperature to quench endogenous peroxidase activity. The sections were washed in running 
tap water. For optimal antigen-binding, an antigen retrieval step was included. 
Antigen retrieval 
Rehydrated paraffin wax sections were optimised for antigen-antibody binding for the 
calcium-binding protein anti-Iba1 (Invitrogen®, cat no  13269248), which is specifically 




(ab7260, AbCam, UK) using 10mM citric acid buffer (pH 6.1) for 15 minutes at 750W power. 
Following thorough washings, sections were equilibrated, for 5 minutes, in PBS (0.1M PBS, 
pH 7.2), and the non-specific antibody binding was controlled by incubating tissue sections 
for 30 min in blocking solution containing 0.1% normal horse serum (Vectastain kit, PK 4002) 
in PBS. AD transgenic Tg2576 mice tissue sections acted as positive controls for 
neuroinflammaton. The negative antibody control sections were incubated in the block 
solution, whereby the primary antibody was omitted. All other tissue sections were incubated 
in a humidity chamber, overnight, at 4ºC in the primary antibodies (rabbit anti-GFAP, 
ab7260, 1/2000) and (rabbit anti-Iba1, 1/150) diluted in blocking solution. The next day, the 
sections were washed in PBS (x3 for 5 mins each) and incubated for 60 min at room 
temperature in the biotin labelled anti-rabbit IgG (from kit PK-4001) diluted 1/200 in block 
solution. From here, the rabbit peroxidase kit (Vector laboratories, Perterborough, UK) and 
the DAB kit (SK-4100) were used as per manufacturers’ instructions. The sections were 
lightly counterstained in Mayer’s haemalum (LAMB/170D) before dehydrating them in 
graded alcohols and clearing in xylene. The sections were mounted under a coverslip and 
examined using the Nikon Eclipse E200 Microscope. Images were captured using the DS-L2 
v.441 Software (Nikon, UK). 
The immunohistochemistry procedure was similar to above for mouse anti-tau (clone AT8, 
Invitrogen®) except antigen retrieval was omitted. The block solution contained PBS-0.1% 
triton X-100, horse serum 0.01%) and the mouse anti-tau antibody was diluted 1/20. The 
secondary detection antibody used was the biotin labelled anti-mouse IgG (from kit PK-4002) 




Gene expression analysis of db/db mice brains 
 
Total RNA extraction 
Total RNA was extracted from ~25 mg brain tissue (fronto-temporal) following a two-step 
procedure. In step 1, the tissue sample was ground in 1 ml TRIzolTM reagent (ThermoFisher 
Scientific Inc.), and total RNA was obtained following the manufacturer’s instructions. In 
step 2, the purification of the total RNA obtained from step 1 was performed following the  
GenElute Total RNA Miniprep Kit (Sigma-Aldrich Corp.) according to the manufacturer’s 




eliminate genomic DNA contamination. Column purification of the RNA was performed 
using GenElute mammalian total RNA miniprep kit (Sigma-Aldrich Corp.). Total RNA was 
finally suspended in 50 μl 0.1% diethylpyrocarbonate (DEPC) treated water and stored at −80 
°C. The quality and quantity of the total RNA were assessed in a NanoDrop-ND1000 
Spectrophotometer (Thermo Fisher Scientific Inc.). The cDNA synthesis was performed with 
1 μg of total RNA using the RevertAid H minus first-strand cDNA synthesis kit (Fermentas 
GmbH, St. Leon-Rot, Germany) following the manufacturer’s protocol. The final volume of 
cDNA was adjusted to 150 μl with nuclease-free water. 
 
Quantitative real-time PCR (qPCR) array 
The expressions of a panel of 192 genes were evaluated using a custom-designed qPCR array 
(Thermo Fisher Scientific Inc), performed in a QuantStudio 5 real-time PCR system (Applied 
Biosystems). The qPCR arrays (96-well format x 2) enabled mRNA screening of a total of 
184 target genes and eight internal controls. The target genes screened included the common 
markers of the inflammatory immune cascade, oxidative stress, glucose metabolism and 
insulin pathways. This panel of genes was previously used to capture the intracellular 
signalling pathways associated with the chronic inflammation induced by P. gingivalis LPS 
treatment [27]. For the qPCR array run, 25 μl cDNA (after 1:5 dilution) from each replicate 
within a single treatment group were pooled. The qPCR was performed on a 20 μl reaction 
mixture per well containing 1 μl pooled cDNA, 9 μl water and 10 μl SYBR green master mix 
(Applied Biosystems). The thermal cycling conditions were 94 °C for 30 s, followed by 60 
°C for 1 min, for 40 cycles. In this experiment, a CT value of 35 was considered as the cut-
off limit. The relative quantities (2–ΔCt) of the target genes were normalized using the 
geometric mean of the relative quantities of three internal control genes (beta-actin (ACTB), 
hypoxanthine-guanine phosphoribosyl transferase 1 (HPRT1) and beta-2 microglobulin 
(B2M). Briefly, average ΔCt was calculated as the difference of Ct values of any target gene 
minus the geometric average of the Ct value of the three reference genes. Then, fold change 
was calculated as 2(− average ΔCt target gene)/2(− average ΔCt reference gene). The 
differentially expressed genes between any two treatments were identified from the ratio of 
fold change values with a cut-off ± 1.8 fold. 
 
Gene Ontology and Pathway Analysis  
Gene ontology (GO) of the differentially expressed genes was performed using the database 




(http://david.abcc.ncifcrf.gov/) bioinformatics tool [28]. The major annotation clusters of GO 
term were identified based on the enrichment score calculated by the DAVID tool’s default 
setting. For pathway analysis, the fold change values were analyzed using Qiagen Ingenuity 
Pathway Analysis (IPA) and the relevant canonical pathways were identified using the 
default setting in the software. The statistical probability (P-value) of the observed number of 
genes affecting a particular biological function was calculated based on Fisher's Exact Test. 
This P-value indicated the statistical probability of the observed number of genes affected out 
of the total number of genes evaluated in the PCR array for the biological function. The 
correlation between the relationship direction and gene expression was determined by 
calculating the Z-score following the formula Z = (N+ − N−)/√ N where N+ represents the 
number of genes whose expression follows the same direction while N− represents the 
number of genes whose expression follows an opposite direction of the expression of a 
particular gene compared to that already available in the IPA knowledge database. N 
indicates the total number of genes affected. A high stringency Z-score between ≥+2.0 or 






Haematoxylin and Eosin morphology staining of the formalin fixed, paraffin wax embedded 
and rehydrated temporal lobe tissue sections from Tg2576, P. gingivilas W83, F. nucleatum 
infected and sham mice showed they were well preserved (not shown). Silver impregnation 
of the tissue sections from the Tg2576 mouse brains demonstrated numerous Aβ plaques, 
which were of variable sizes, randomly distributed, within the fronto-temporal cortices 
including the hippocampus (Fig. 1a). The argyrophilicAβ plaques and NFTs were absent in 
the hippocampus or in the fronto-temporal cortices of db/db brain tissue sections, from  the P. 









The negative controls whereby the primary antibody was omitted remained negative (Fig. 2a-
d). In theTg2576 mice (Fig. 2e arrows), and the sham (Fig. 2f arrows) and the F. nucleatum 
infected (Fig. 2g arrows) activated microglia were below the threshold of the numbers (not 




Anti-GFAP immunostaining of the AD trangenic Tg2576 mice brain sections demonstrated 
the presence of abundant, reactive, astrocytes in close vicinity to the Aβ plaques (Fig 3a box, 
b, where p represents the Aβ1-42 plaque core and is the area within the box from Fig. 3a). The 
sham-infected mice  brain tissue sections (Fig. 3c box, d area within the box in 3c) 
demonstrated resting astrocytes. F. nucleatum infected mouse hippocampus demonstrated 
significant numbers (not counted) of activated, astrocytes (Fig. 3e box, f area within the box 
in 3e). The P. gingivalis W83 infected mice brain tissue sections (Fig. 3g area within the 
smaller box is represented in h and i is the are area from the larger box in 3g) also 
demonstrated an abundance of reactive astrocytes almost equivalent (not counted) to those 
observed in F. nucleatum infected mice tissue sections (Fig. 3e, f).  
 
 
Mouse anti-tau (AT8) immunostaining for detecting neurofibrillary tangles 
As expected, the AD trangenic Tg2576 mice exhibited an intense immunopositive staining 
for tau within numerous CA neuronal cell bodies. The axon hillock of some neurons was also 
immunostained (Fig. 4a arrows). Overall the tau staining in the sham (non-infected) group of 
mice was weak (Fig. 4b and arrow). In the F. nucleatum mice, a weak tau immunostaining 
was observed within the CA neurons without evidence of staining within the axon hillocks 
(Fig. 4c). The P. ginivalis W83 infected mice demonstrated tau immunostaining within the 
CA neurons (Fig. 4d) and equally stronger tau positivity within thickened bundles of axonal 
hillocks in the hippocampal CA neurons (Fig. 4e boxed area shown in f, arrows point to 
thickened axonal hillocks).  
 
Gene expression in brains using qPCR array 
 
Of the total 192 genes evaluated on the qPCR array, the mRNA of 184 genes were detectable. 




expressed due to the P. gingivalis W83 induction of obese diabetic mice (Table 1). The 
primary group of genes upregulated (by >2 fold) by P. gingivalis W83 infection within the 
extracellular space of the cells includes the growth factor IGF1 and several cytokines 
(IL1A, IL1B, CSF1, LTA and CXCL10). Other genes upregulated in the extracellular space 
include IGFBP3, CRP and RETN. In the plasma membrane, genes upregulated include 
transmembrane receptor (IGF1R, TLR4, TLR6, ICAM1, VCAM1, IL6R, IL1R2, CD28, CD80), 
G-protein coupled receptor (ADORA1, CCR2, GLP1R, GLP2R) and membrane transporters 
(LDLR). Besides, the mRNA abundance of two crucial kinases (INSR, KDR) and plasma 
membrane-associated enzymes (ACE, ADA, DPP4, PTPRC) and other molecules (DOK2, 
CLTC, MYD88, CAP1) were also upregulated by >2 fold. As expected, within the cytoplasm, 
the major group of molecules affected were kinases (AKT1, PIK3R1, PIK3R2, PRKCA, 
PRKCB, PRKCD, JAK2 etc.) and enzymes (Table 1). The mRNA abundance of 12 
transcription factors (FOXO1, NFKB2, NFATC2, CTNNB1, FOS, SREBF1, SREBF2, TRP53, 
STAT3, JUN, SMAD7 and CBL ) were also upregulated whilst two transcription factors 
(CREB1 and STAT6) were down-regulated. Other genes differentially expressed within the 
nucleus included ligand-dependent nuclear receptor (NR4A2), nuclear kinase (GSK3B), 
enzymes (APC, AEBP1) and other molecules (CDC27). 
 
Annotation clustering and gene ontology 
An evaluation of the panel of differentially expressed genes revealed the major annotation 
clusters and gene ontologies associated with the molecular, biological and cellular processes 
altered in the cerebral hemisphere of the db/db mice induced with P. gingivalis W83. A total 
of 13 annotation clusters with an enrichment score of ≥2.0 were scored, of which four most 
relevant clusters with the highest scores are presented in Table 2. Cluster 1 (enrichment score 
7.97) includes the well-represented gene ontology (GO) terms relating to protein 
phosphorylation, kinase activity, transferase activity, intracellular signal transduction, ATP 
binding and nucleotide bindings indicating that the genes differentially expressed by the P. 
gingivalis W83 induction are likely to affect these intracellular processes (Fig. 5a). Cluster 2 
(enrichment score 4.06) relates to the inflammatory immune response (Fig. 5b). Two other 
highly enriched annotation clusters (Cluster 3 and 4) include GO terms relating to insulin and 
insulin receptor signalling pathways (Fig 5c and 5d).  
 




The list of most relevant intracellular signaling pathways and the number of gene affected 
within each of these pathways due to P. gingivalis W83 induction of mice versus F. 
nucleatum and sham control groups are presented in Table 3. The pathway analysis revealed 
that classical signaling associated with inflammatory immune response (NF-kB signaling, 
neuroinflammatory signaling, toll-like receptor signaling, LPS mediated MAPK signaling, 
IL1 and IL6) upregulated in the P. gingivalis W83 infected mice brains. Besides, pathways 
for cell growth, survival and proliferation (IGF-1 signaling, PI3K/AKT, PTEN and mTOR 
signaling pathways) and cellular metabolism and insulin signaling (PPAR, insulin receptor 
signaling, insulin secretion pathways and T2D signaling) were affected in the P. gingivalis 
W83 induced mice. As expected, these pathways were mostly unaffected when assessed in 





This study aimed to investigate the effect of Porphyromonas gingivalis (W83) oral infection 
on the development of AD pathophysiology in an obese, diabetic (db/db) mouse model. The 
Aβ insoluble plaque hallmark of AD in a wild-type young mouse model of periodontitis 
following an oral infection with the highly virulent strain of P. gingivalis W83 (capsular K1 
serotype) has been previously reported [29]. This was the first report which demonstrated 
classical human AD look-alike Aβ plaque deposits in the hippocampus of a mouse model of 
periodontal disease, which would be expected to be demonstrated by neutral histology stains 
such as silver impregnation used in the present study.  
Encouraged by the Ilievski et al. [29] data, and based on the knowledge that 
periodontal disease, cardiovascular disease, diabetes (MetS) represent a greater risk of 
dementia for individuals who have suffered multiple co-morbidities in their lives 
[8,9,22,23,30], we used a co-morbid disease db/db mouse model  to reproduce the cardinal 
hallmark lesions of AD, following an oral infection with the same strain of P. gingivalis 
(W83) [29].  However, in db/db mice, the classical AD Aβ plaques and NFT formation were 
not observed in the hippocampus or any other anatomical regions of the brain following the 
silver impregnation of tissue sections. Regarding anti-tau immunostaining, our observations 
are similar to the Díaz-Zúñiga et al. [14]  study in which oral infections of rats with several 




classical AD Aβ plaques shown by Ilievski et al. [29]. An underlying reason behind the lack 
of Aβ deposition in the present study could be that the mice were obese and of diabetic 
dispostionand not of healthy wild-type phenotype. A high level of circulating insulin is a 
hallmark of insulin resistance and could  prevent Aβ and NFT accumulation [31]. Insulin can 
potentially increase the activities of anti-amyloidgenic proteins such as insulin-degrading 
enzyme (IDE) and inhibit the phosphorylation of tau by glycogen synthase kinase-3b 
(GSK3B) activity [31,32]. This led us to change the course of our investigation into gene 
array methodology for early clues to AD pathophylogical changes in the oral infection 
mediated periodontal model for AD.   
However, before moving on, Díaz-Zúñiga et al. [14] observed thickened axons in the 
hippocampal neurons of P. gingivalis (capsular forms) infected rat brains which they 
suggested  were equivalent to the human AD NFT lesion [14].  In the present study, 
following anti-tau immunostaining we also observed thickened axon hillocks of cortical 
hippocampal neurons reported by Diaz-Zuniga et al. [14], which contrasts with the 
explanation offered by Pandini et al [31] and Cholerton et al. [32]. Díaz-Zúñiga et al. [14] 
and Ilievski et al. [29]  also observed neuroinflammation with the capsulated P. gingivalis 
strains as originally reported by Poole et al. [33]  in their P. gingivalis (strain 381, non-
capsulated, K0 serotype) mono-infected apolipoprotein knockout mouse model. In the db/db 
mouse model, F. nucleatum infected mouse hippocampi demonstrated significant numbers of 
activated, astrocytes but not microglia. This was an interesting observation showing that even 
a non-pathogenic bridging bacterium like F. nucleatum can stimulate astrocytes but a 
stronger immune stimulation from the pathogenic P. gingivalis W83 infected mice brain 
tissue sections demonstrated abundant reactive microglia. All these reports confirm that an 
oral infection with P. gingivalis in rodents always leads to an inflammatory intracerebral 
episode as in humans after an infectious episode [34] which has been associated with 
cognitive deficit [35].  
When  we evaluated the  gene expression analysis of a panel of 184 genes that were 
altered due to P. gingivalis (W83) oral infection, we observed that the pathways of insulin 
signaling and neuroinflammatory immune response mediated by PI3K/AKT1 were 
hyperactivated in the brain in response to the P. gingivalis infection demonstrating the 
potential of P. gingivalis W83 induced co-morbidity in the mice model of AD. 
In the present study, the P. gingivalis infection mediated the activation of insulin 




pathways involve multiple signalling routes, potentially contributing to AD pathophysiology 
(Fig. 6). The mammalian brain, a highly insulin-sensitive organ, heavily depends on insulin 
to utilise glucose as an energy source and support cognitive functions [36]. Endogenous 
insulin released by the pancreas crosses the blood-brain barrier to enter the neural tissue of 
the brain but our results suggest a plausible activation of a localised insulin secretion in the 
hippocampus following the P. gingivalis infection. Our gene expression pathway analysis 
identified 11 genes (GLP1R, INSR, JAK2, PIK3R1, PIK3R2, PRKACA, PRKAR1A, PRKCA, 
PRKCB, PRKCD and STAT3) whose mRNA abundance indicated activation of a localised 
insulin secretion mechanism in the hippocampal region. One potential route of insulin 
secretion in the brain is via glucagon-like peptide 1 (GLP-1) and protein kinase [37]. During 
a hyperglycemic state, GLP-1 in the brain is able to cross the blood-brain barrier [38] and 
inhibit glucose utilisation and cause insulin secretion [39,40]. In this study, P. gingivalis 
induction resulted in a higher mRNA abundance of GLP1R and several kinases and their 
receptors and lower mRNA abundance of G6P, a key glucose utilisation marker. The adult 
neuronal cells of the hippocampus were previously reported to secrete insulin [41]. A 
localised synthesis of insulin in the brain may be a compensatory mechanism linked to the 
insulin resistance that has the potential to develop following P. gingivalis infection and its 
mechanims of action warrants further research.   
AD is a neurodegenerative disease being linked to MetS often characterised by insulin 
resistance, oxidative stress and neuroinflammation [42-44]. As identified through 
pathway/GO analyses, a higher level of insulin activity in the brain potentially causing insulin 
resistance was also evident from the increased mRNA levels of key markers of the 
insulin/insulin-like growth factor-1 (IGF-1) pathways. For example, the P. gingivalis 
infection increased the mRNA abundance of  IGF1, insulin receptor (IR), IGF-1 receptor 
(IGF1R) and IGF binding protein (IGFBP3) genes. While the shared IR/IGF1R system in the 
plasma membrane of hippocampal cells is crucial for normal insulin signalling. Binding of 
IGFBP-3 to IGF-1 can potentially contribute to glucose intolerance and insulin resistance in 
the brain [45]. An interesting protein in the IR/IGF1R system is the insulin receptor substrate 
1 (IRS-1), a docking protein, which is a primary checkpoint for the insulin signalling pathway 
and glucose metabolism regulation [42].  The normal physiological activation of the insulin 
signalling is achieved by binding insulin to the insulin receptor within the extracellular matrix 
resulting in the phosphorylation of IRS-1 at the tyrosine residue. However, phosphorylation 




gingivalis infection  increased the mRNA abundance of the IRS1 gene. Whether an increased 
level of IRS1 mRNA due to the P. gingivalis infection in this study is associated with 
phosphorylation at the serine residues, thereby contributing to the insulin resistance requires 
further investigation. 
The interaction of insulin/IGF-1 to the IR/IGF1R receptor system triggers the release 
of IRS-1/2 and subsequent activation of the phosphatidylinositol 3-kinase type I (PI3K)/AKT 
pathways [42]. Our gene expression profiling indicated  P. gingivalis infection activates 
multiple pathways that  potentially lead to hyperactivation of the PI3K/AKT pathway genes. 
These include numerous mRNA markers of the IR/IGF1R, LPS/TLR and MAPK pathways 
(Fig. 5). The PI3K/AKT1 pathway plays a vital role in the metabolism of nutrients and 
maintains cellular homeostasis essential for cell growth, survival and differentiation [47]. 
An impaired insulin/PI3K/AKT1 pathway activity can contribute to the onset of 
neurodegenerative diseases [47,48]. During the cellular oxidative stress, PI3K, together with 
AKT1, triggers reactive osygen species (ROS) production [49,50]. The hyperactivation of 
PI3K/AKT pathway resultes in lower nitric oxide (NO) production, higher ROS activities, 
and a higher level of pro-inflammatory cytokines, which are known to culminate in the 
pathophysiology of AD [42]. A conspicuous decrease in the mRNA abundance of nitric oxide 
synthase 2 (NOS2) by P. gingivalis infection observed  in this study further suggests 
potentially a lower level of NO synthesis. Other mechanisms of AKT-mediated response 
include affecting glucogenesis, lipolysis and mTOR-mediated protein synthesis, leading to 
impaired autophagy and synaptic plasticity associated with AD pathophysiology [48]. The 
pathway analysis also revealed inhibition of the phosphatase and tensin homolog (PTEN), a 
tumour suppressor molecule that catalyses the conversion of PIP3 to PIP2 and reverses the 
PI3K/AKT activities. Inhibition of the PTEN pathway is likely to contribute to the 
hyperactivation of PI3K/AKT pathways.    
In the present study, the mRNA abundance of AKT1 and its three crucial downstream 
cascades triggered by the action of GSK3B, FOXO1 and NFKB2 genes as they were 
upregulated by P. gingivalis infection. Hyperactivity of AKT1 may lead to excessive 
phosphorylation of GSK-3B, FOXO1 and NF-kB, resulting in several consequences that 
affect metabolic and cognitive functions [47]. AKT1/GSK-3B hyperactivation causes 
abnormal phosphorylation of tau, leading to neurofibrillary tangle formation, a hallmark of 
AD pathophysiology [42,51]. In this study, the mRNA abundance of both AKT1 and GSK3B 




was also evident in the hippocampal neurons with thickened bundles of axon hillock(s) in the 
hippocampus. P. gingivalis infection inducing greater phosphorylated tau was also reported 
by other recent studies [29,52]. AKT1/GSK-3B hyperactivation can also promote a pro-
inflammatory state through phosphorylation of STAT3. This transcription factor  is required 
to induce pro-inflammatory cytokines [53], and its mRNA abundance was also increased 
confirming previous reports for P. gingivalis infection mediated cytokine release [3]. We 
have previously demonstrated that P. gingivalis LPS increased the mRNA abundance of 
GSoK3B, STAT3 and CREB1 genes in the IMR-32 neuronal cell model [27]. In this study, 
while the mRNA abundance of GSK3B, STAT3 genes increased due to P. gingivalis infection, 
that of CREB1 gene decreased. The P. gingivalis mediated induction of pro-inflammatory 
responses is likely to include LPS and gingipain virulence factors [9], and it is a multi-
component signaling cascade that is likely to be induced that may negatively impact on tau 
hyperphosphorylation. 
The activation of the AKT1/FOXO1cascade results in enhanced transcriptional 
activity of FOXO1 that can lead to hyperglycemia and ROS production, and thus insulin 
resistance and oxidative stress [54]. FOXO1 can also activate c-Jun N-terminal kinase and 
inhibit Wingless (Wnt) pathways and can contribute to Aβ plaque formation and 
phosphorylation of tau, potentially leading to neurodegeneration [54]. The FOXO1 within the 
nucleus activates the transcription of many inflammatory mediators. In the present study, the 
mRNA abundance of FOXO1, and that of a few downstream molecules such as pro-
inflammatory cytokines (IL1B), wound healing factor (VEGF), and adhesion molecule 
(VCAM1) were increased. Together these observations suggest that P. gingivalis infection 
does indeed hyperactivate the AKT1/FOXO1 cascade, and could potentially exacerbate the 
insulin resistance and oxidative stress pathways.  
In the present study, the mRNA abundance of the NF-kB cascade (NFKB2, IKBKB) 
and pro-inflammatory cytokines (LTA, IL1A, IL1B, IL6R, CSF1) were upregulated by the P. 
gingivalis infection. The AKT1/NF-kB signaling plays a crucial role in the inflammatory 
response, oxidative stress, activation of microglia, and apoptotic cell death, thereby  
contributing to neurodegeneration [55]. The NF-kB has both neuroprotective and 
neurodegenerative roles in AD. One of the mechanisms through which NF-kB contributes to 
AD is mediated by activation of βsite APP cleaving enzyme 1 (BACE1). An excessive 
cleavage of amyloid-beta precursor protein (A PP) leads to A  plaque deposition [56]. The 




regulated due to the P. gingivalis infection in db/db mice. Inhibition of PPAR activities may, 
therefore, lead to the higher activity of BACE1 [57]. 
Individuals with periodontal disease have an increased risk for cardiovascular 
pathologies and AD. Subjects with predisposing factors like MetS, obesity and diabetes, are 
at greater risk of developing periodontal disease and AD [58]. The db/db mouse model tested 
here provided a unique opportunity to explore the associations between obesity, diabetes and 
periodontitis on the development of AD. Our observations from the present study  provides 
further support to the notion that AD is an inflammatory disease affected by peripheral 
(systemic) [23,59,60], and intracerebral inflammatory events which ultimately impact on 
cognitive decline [61,62].  
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Differential expression of genes caused by the P. gingivalis W83 (PG) induction of the db/db mice versus the F. nucleatum (FN) or sham 
infection in the cerebral hemisphere region of the brain (fold change values ≥ 2.0 and ≤− 2.0 folds in the P. gingivalis group and in the 
corresponding groups. 
 
Gene Location Type of molecule PG vs FN PG/sham FN/sham 












Growth factor +3.47 +2.25 -1.54 
C-X-C motif chemokine ligand 10 (CXCL10) Cytokine +2.30 +1.78 -1.29 
Interleukin 1 alpha (IL1A) Cytokine +2.22 +1.90 -1.17 
Lymphotoxin alpha (LTA) Cytokine +2.17 +2.69 +1.24 
Colony stimulating factor 1 (CSF1) Cytokine +2.13 +2.06 -1.03 
Interleukin 1 beta (IL1B) Cytokine +2.07 +2.63 +1.27 
Matrix metallopeptidase 2 (MMP2) Peptidase +3.35 +3.62 +1.08 
Insulin degrading enzyme (IDE) Peptidase +2.19 +1.77 -1.24 
Resistin (RETN) Other +6.11 +1.53 -3.99 
insulin like growth factor binding protein 3 
(IGFBP3) Other +3.42 +3.42 +1.00 
C-reactive protein (CRP) Other +2.02 +2.56 +1.27 











Transmembrane receptor +7.43 +7.21 -1.03 
Interleukin 6 receptor (IL6R) Transmembrane receptor +6.05 +3.42 -1.77 
Intercellular adhesion molecule 1 (ICAM1) Transmembrane receptor +5.32 +3.43 -1.55 
interleukin 1 receptor type 2 (IL1R2) Transmembrane receptor +4.73 +2.27 -2.08 
CD 80 molecule (CD80) Transmembrane receptor +2.78 +2.01 -1.39 
CD 28 molecule (CD28) Transmembrane receptor +2.73 +1.93 -1.41 
Vascular cell adhesion molecule 1 (VCAM1) Transmembrane receptor +2.15 +1.79 -1.20 
Toll like receptor 6 (TLR6) Transmembrane receptor +2.15 +2.13 -1.01 




Glucagon like peptide 1 receptor (GLP1R) G-protein coupled receptor +5.96 +2.07 -2.88 
Glucagon like peptide 2 receptor (GLP2R) G-protein coupled receptor +4.61 +2.32 -1.99 
C-C motif chemokine receptor 2 (CCR2) G-protein coupled receptor +3.67 +2.10 -1.74 
Adenosine Receptor A1 (ADORA1) G-protein coupled receptor +2.03 +4.12 +2.03 
Low density lipoprotein receptor (LDLR) Transporter +3.50 +3.48 -1.01 
LDL receptor related protein 2 (LPR2) Transporter -3.08 -2.07 +1.49 
Insulin receptor (INSR) Kinase +3.35 +1.33 -2.52 
Kinase insert domain receptor (KDR) Kinase +2.89 +1.96 -1.47 
Fibroblast growth factor receptor 4 (FGFR4) Kinase +2.58 +1.92 -1.35 
Epidermal growth factor receptor (EGFR) Kinase +2.58 +1.26 -2.06 
Protein tyrosine phosphatase receptor type C 
(PTPRC) Phosphatase +2.74 +1.63 -1.68 
Angiostensin I converting enzyme (ACE) Peptidase +5.36 +3.47 -1.54 
Dipeptidyl peptidase 4 (DPP4) Peptidase +2.21 +1.65 -1.34 
Adenosine deaminase (ADA) Enzyme +2.88 +2.24 -1.28 
Docking Protein 2 (DOK2) Other +4.90 +3.18 -1.54 
Clathrin heavy chain (CLTC) Other +3.33 +2.76 -1.20 
MTD88 innate immune signal transduction adaptor 
(MYD88) Other +2.08 +3.43 +1.65 
Cyclase associated actin cytoskeleton regulatory 
protein 1 (CAP1) Other +2.05 +2.84 +1.38 








Enzyme +4.30 +6.42 +1.49 
Hydroxysteroid 17-beta dehydrogenase 4 Enzyme +2.42 +4.70 +1.94 
KRAS proto-oncogene, GTPase (KRAS) Enzyme +2.30 +2.44 +1.06 
Insulin receptor substrate 1 (IRS1) Enzyme +2.20 +1.93 -1.14 
Nitric oxide synthase 2 (NOS2) Enzyme -4.64 -4.25 +1.09 
Mitogen-activated protein kinase 7 (MAPK7) Kinase +3.75 +1.58 -2.37 
Phosphoinositide-3-kinase regulatory subunit 2 




Component of inhibitor of nuclear factor kappa B 
kinase complex (CHUK) Kinase +3.38 +2.15 -1.57 
ATP serine/threonine kinase 1 (AKT1) Kinase +2.87 +3.79 +1.32 
Protein kinase cAMP-dependent type I regulatory 
subunit 1A (PRKAR1A) Kinase +2.74 +3.05 +1.11 
Mitogen-activated protein kinase kinase kinase 1 
(MAP3K1) Kinase +2.69 +1.65 -1.63 
Protein kinase C beta (PRKCB) Kinase +2.58 +2.43 -1.06 
Phosphoenolypyruvate carboxykinase 2, 
mitochondrial (PCK2) Kinase +2.56 +4.25 +1.66 
Protein kinase cAMP-activated catalytic subunit 
alpha (PRCAKA) Kinase +2.55 +4.83 +1.90 
Adenylate Kinase 2 (AK2) Kinase +2.45 +3.93 +1.61 
Protein kinase C beta (PRKCA) Kinase +2.41 +2.32 -1.04 
Raf-1 proto-oncogene, serine/threonine kinase 
(RAF1) Kinase +2.39 +2.63 +1.10 
Phosphoinositide-3-kinase regulatory subunit 1 
(PIK3R1) Kinase +2.37 +2.80 +1.18 
Serum/glucocorticoid regulated kinase 1 (SGK1) Kinase +2.33 +1.68 -1.39 
Interleukin 1 receptor associated kinase 4 (IRAK4) Kinase +2.25 +1.22 -1.85 
Protein kinase C delta (PRKCD) Kinase +2.20 +2.23 +1.01 
Serum/glucocorticoid regulated kinase 3 (SGK3) Kinase +2.13 +1.96 -1.09 
Janus kinase 2 (JAK2) Kinase +2.13 +1.32 -1.62 
Inhibitor of nuclear factor kappa B kinase subunit 
beta (IKBKB) Kinase +2.01 +2.66 +1.32 
Caspase 7 (CASP7) Peptidase +2.53 +4.11 +1.62 
Protein phosphatase 2 scaffold subunit A alpha 
(PPP2R1A) Phosphatase +2.08 +4.45 +2.14 
Glucose 6 phosphatase catalytic subunit (G6PC) Phosphatase -2.53 -1.07 +2.37 
Adenosine A2a receptor (ADORA2A) G-protein coupled receptor +2.34 +2.35 +1.01 




Adaptor related protein complex 1 subunit sigma 2 
(AP1S2) Transporter +3.90 +1.91 -2.04 
Adaptor related protein complex 1 subunit sigma 1 
(AP1S1) Transporter +2.29 +4.07 +1.78 
Uncoupling protein 2 (UCP2) Transporter +2.18 +1.30 -1.68 
Growth factor receptor bound protein 10 (GRB10) Other +4.05 +1.36 -2.97 
Tubulin beta class I (TUBB) Other +2.68 +3.14 +1.17 
GRB2 associated binding protein 1 (GAB1) Other +2.40 +2.08 -1.16 
SOS Ras/Rho guanine nucleotide exchange factor 2 
(SOS2) Other +2.27 +1.85 -1.23 
Growth factor receptor bound protein 2 (GRB2) Other +2.14 +3.81 +1.78 
CRK proto-oncogene, adaptor protein (CRK) Other +2.01 +2.51 +1.25 
Suppressor of cytokine signaling 1 (SOCS1) Other -2.21 +1.49 +3.30 






Transcription regulator +4.00 +3.35 -1.20 
Nuclear factor kappa B subunit 2 (NFKB2) Transcription regulator +4.68 +3.77 -1.24 
Nuclear factor of activated T cells 2 (NFATC2) Transcription regulator +2.82 +3.25 +1.15 
Catenin beta 1 (CTNNB1) Transcription regulator +2.71 +1.91 -1.42 
Fos proto-oncogene, AP-1 transcription factor 
subunit (FOS) Transcription regulator +2.71 +2.10 -1.29 
Sterol regulatory element binding transcription factor 
1 (SREBF1) Transcription regulator +2.69 +2.93 +1.09 
Tumor protein p53 (TP53) Transcription regulator +2.62 +3.13 +1.20 
Sterol regulatory element binding transcription factor 
2 (SREBF2) Transcription regulator +2.31 +2.89 +1.25 
Signal transducer and activator of transcription 3 
(STAT3) Transcription regulator +2.31 +3.15 +1.36 
Jun proto-oncogene, AP-1 transcription factor 
subunit (JUN) Transcription regulator +2.21 +3.35 +1.52 
SMAD family member 7 (SMAD7) Transcription regulator +2.10 +1.74 -1.21 




Signal transducer and activator of transcription 6 
(STAT6) Transcription regulator -3.41 -2.23 +1.53 
cAMP responsive element binding protein 1 
(CREB1) Transcription regulator -4.76 -2.23 +2.13 
Nuclear receptor subfamily 4 group A member 2 
(NR4A2) 
Ligand-dependent nuclear 
receptor +2.45 +3.55 +1.45 
Glycogen synthase kinase 3 beta (GSK3B) Kinase +4.78 +2.42 -1.97 
APC regulator of WNT signaling pathway (APC) Enzyme +2.73 +1.26 -2.16 
AE binding protein 1 (AEBP1) Peptidase +4.00 +2.29 -1.75 








The major gene annotation clusters of gene ontology (GO) affected by the genes 
differentially expressed in the mice brain due to the P. gingivalis W83 induction compared to 


















GO:0006468~protein phosphorylation 25 26.32 1.3E-15 
GO:0016301~kinase activity 24 25.26 8.2E-13 
GO:0016310~phosphorylation 22 23.16 4.4E-12 
GO:0004672~protein kinase activity 20 21.05 4.8E-11 
GO:0035556~intracellular signal 
transduction 
14 14.74 1.5E-07 
GO:0018105~peptidyl-serine 
phosphorylation 
9 9.47 4.5E-07 
GO:0046777~protein 
autophosphorylation 
10 10.53 4.6E-07 
GO:0004674~protein serine/threonine 
kinase activity 
14 14.74 4.8E-07 
GO:0005524~ATP binding 23 24.21 1.2E-05 
GO:0000166~nucleotide binding 26 27.37 2.3E-05 
GO:0016740~transferase activity 22 23.16 2.9E-05 












GO:0006954~inflammatory response 13 13.68 2.2E-07 
GO:0006955~immune response 9 9.47 8.6E-05 














9 9.47 2.1E-10 
GO:0048009~insulin-like growth 
factor receptor signaling pathway 
6 6.32 2.6E-09 
GO:0032869~cellular response to 
insulin stimulus 













factor receptor signaling pathway 
6 6.32 2.6E-09 
GO:0005159~insulin-like growth 
factor receptor binding 
5 5.26 5.4E-07 
GO:0005158~insulin receptor binding 6 6.32 1.2E-06 
GO:0046326~positive regulation of 
glucose import 
5 5.26 2.5E-05 
GO:0045725~positive regulation of 
glycogen biosynthetic process 






4 4.21 2.9E-04 
GO:0043491~protein kinase B 
signaling 













































































































Inflammatory Cascade  
NF-kB 179 25 ↑ +4.600 3.0e-32 23 ↑ +4.379 3.7e-30 7 ↓ -1.890 4.1e-10 
Neuroinflammation 315 27 ↑ +3.530 6.2e-29 23 ↑ +2.711 2.2e-24 6 ↓ -0.816 6.1e-07 
LPS stimulated MAPK 83 14 ↑ +3.207 1.5e-19 15 ↑ +3.350 3.3e-22 0 ↔ - - 
PI3K/AKT 189 20 ↑ +1.500 2.4e-23 23 ↑ +2.065 1.4e-29 3 ↔ - - 
Toll-like receptor 77 12 ↑ +3.000 1.8e-16 10 ↑ +2.646 1.3e-13 3 ↔ - - 
Interleukin 1 95 11 ↑ +3.317 1.1e-13 9 ↑ +3.000 4.2e-11 2 ↔ - - 
Interleukin 6 126 20 ↑ +4.472 5.0e-27 19 ↑ +4.359 2.4e-26 3 ↔ - - 
mTOR 216 10 ↑ +2.530 1.3e-08 10 ↑ +2.530 3.9E-09 2 ↔ - - 
Diabetes              
Insulin-like growth factor1 106 20 ↑ +3.771 1.2e-28 19 ↑ +3.500 7.0e-28 3 ↔ - - 
Insulin receptor 145 20 ↑ +2.683 9.8e-26 16 ↑ +2.000 5.1e-20 5 ↓ -1.342 3.2e-07 
Insulin secretion 267 13 ↑ +2.496 3.9e-11 12 ↑ +2.309 1.4e-10 5 ↑ +0.447 6.5e-06 
Type-2 diabetes 163 13 ↑ +2.714 7.4e-14 11 ↑ +2.530 1.1e-11 4 ↔ - - 
Other              
PPAR 105 13 ↓ -3.600 2.2e-16 15 ↓ ̶ 3.873 1.4e-20 3 ↔ - - 







Figure and legends 
 
Figure 1 
Rehydrated paraffin wax embedded brain tissue sections from  the hippocampus of the AD 
transgenic Tg2576 (ADtg) mice and obese diabetic mice stained with methenamine silver to 
demonstateinsoluble amyloid-beta (Aβ) plaques. 
a) AD transgenic mouse (positive control for Aβ plaques). Methenamine silver shows 
numerous argyrophilic plaques of variable size in the hippocampus in close proximity to 
the CA neurons. Some blood vessels stand out following silver impregnation. 
b) Sham infected (sham) obese diabetic mice 
c) F.m nucleatum (FN) 
d) P. gingivalis (Pg W83), images b-d) from obese diabetic mice completely lacked Aβ 
plaques This image shows immunostaining with mouse anti-tau (AT8) antibody to detect 









Rehydrated paraffin wax tissue sections and order of brains as for figure 1. This image shows 
immunostaining with rabbit anti-Iba-1 antibody to detect activated microglia.  
Images a-d) show little staining as a negative control as when the primary antibody was 
omitted in all mice categories.  
Images e-i) show variable degree of activated microglia scattered within the hippocampusas 
denoted by arrows. In the sham-infected (2f) and the F. nucleatum infected (2g) mice, 
showed only a few resting microglia. The P. gingivalis W83 mice demonstrated considerably 
more reactive microglial cell distribution with branched processes within the hippocampus 







Rehydrated paraffin wax tissue sections and order of brains as for figure 1.  
Immunolabelling of the GFAP  
The AD trangenic mice brain sections (a-b) demonstrate numerous reactive astrocytes in 
close vicinity to the amyloid plaques (3a box, and b where p represents the amyloid plaque 
core and is the area within the box from 3a).  
The sham brain sections (3c box, d area within the box in 3c) demonstrated resting astrocytes. 
F. nucleatum infected mice hippocampus (e-f) demonstrated a significant numbers of 
activated astrocytes (3e box, f area within the box in 3e).  
The P. gingivalis W83 brain sections, (3g box, h and i are areas from box in 3g) also 







Rehydrated paraffin wax tissue sections and order of brains as for figure 1. This image shows 
immunostaining with mouse anti-tau (AT8) antibody to detect neurofibrillary tangles.  
a) The AD trangenic mice exhibited an intense immunopositive staining within 
neurmerous CA neuronal cell bodies within the hippocampus. The axon hillock of 
some neurons was also immunostained (4a and arrows).  
b) Sham infected mice demonstarted some inconspicuous stating in the axon hillock (4b 
and arrow).  
c) In the F. nucleatum mice, a weak, largely diffuse tau immunostaining was observed 
within the CA neurons without evidence of staining within the axon hillock (4c).  
d) The images d to f) are tissue sections from P. ginivalis W83 infected mice 
demonstrating tau immunostaining within the CA neurons and more stronger tau 








Gene annotation clusters of gene ontology (GO) term relating to kinases (a) and 
inflammatory immune response (b), insulin/IGF-1 signaling (c) and insulin/IGF-1 receptors 
(d) and the candidate gene/s associated with the GO term. The GO analysis was performed 
based on the 96 differentially expressed genes caused by the  P. gingivalis W83 induction in 
the db/db mice compared to those treated with the Fusobacterium nucleatum (control). Two 
major clusters (Cluster 1 and 2) relating to kinases and inflammatory immune response and 











Schematic outline of four major pathways (PI3K/AKT pathway, MAPK pathway, Insulin 
signaling pathway and TNF pathway) affected in the db/db mice due to the P. gingivalis W83 
induction.  These interconnected pathways lead to altered activities of kinases (PI3K/AKT1, 
RAS/MEKK1)), affect insulin signaling (IRS1) and nutrient metabolism (AKT1), alter 
oxidative stress (NOS2), transcriptional activation pro-inflammatory genes (NFKB, AP1, 
cFOS), all potentially contributing to Alzheimer’s disease pathophysiology (A  plaque and 
Tau neurofibrillary tangles). The mRNA abundance of the markers as found in this study to 
increase (up arrow) or decrease (down arrow) following the P. gingivalis W83 treatment 
compared to those of the F. nucleatum infection are shown. The stimulatory and inhibitory 
relationship of the molecules are shown as arrow and hammer signs, respectively.  
 
